Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Details) - Segments Information

v3.19.2
SEGMENT INFORMATION (Details) - Segments Information - USD ($)
 3 Months Ended 6 Months Ended
Apr. 30, 2019
Apr. 30, 2018
Apr. 30, 2019
Apr. 30, 2018
Oct. 31, 2018
Net loss:          
Net Loss $ (2,574,934) $ (1,392,514) $ (7,541,543) $ (3,257,988)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 1,521,784 1,819,244 3,755,348 3,426,857  
Plus non-cash share-based compensation expense 1,321,450 331,710 4,071,614 598,683  
Total operating costs and expenses 2,843,234 2,150,954 7,826,962 4,025,540  
Total assets:          
Total Assets 7,765,426   7,765,426   $ 6,448,542
Operating Segments [Member] | Cancer Diagnostics [Member]          
Net loss:          
Net Loss (1,248,001) (739,202) (3,052,355) (1,362,451)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 658,433 549,866 1,417,967 1,075,480  
Total assets:          
Total Assets 3,605,773   3,605,773   2,545,803
Operating Segments [Member] | Cancer Therapeutics [Member]          
Net loss:          
Net Loss (1,029,934) (442,049) (3,517,219) (1,551,067)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 444,890 393,645 1,245,681 1,348,498  
Total assets:          
Total Assets 2,939,717   2,939,717   2,157,359
Operating Segments [Member] | Patent Licensing [Member]          
Net loss:          
Net Loss (296,999) (211,263) (971,969) (344,470)  
Operating costs and expenses excluding non-cash share based compensation expense:          
Operating costs and expenses 418,461 $ 875,733 1,091,700 $ 1,002,879  
Total assets:          
Total Assets $ 1,219,936   $ 1,219,936   $ 1,745,380